Abstract
Parkinson's disease (PD), a common neurodegenerative disorder characterized by progressive loss of dopaminergic neurons and their terminations in the basal ganglia, is thought to be related to genetic and environmental factors. Although the pathophysiology of PD neurodegeneration remains unclear, protein misfolding, mitochondrial abnormalities, glutamate dysfunction and/or oxidative stress have been implicated. In this study, we report that a rare T1492G variant in GLUD2, an X-linked gene encoding a glutamate dehydrogenase (a mitochondrial enzyme central to glutamate metabolism) that is expressed in brain (hGDH2), interacted significantly with age at PD onset in Caucasian populations. Individuals hemizygous for this GLUD2 coding change that results in substitution of Ala for Ser445 in the regulatory domain of hGDH2 developed PD 6–13 years earlier than did subjects with other genotypes in two independent Greek PD groups and one North American PD cohort. However, this effect was not present in female PD patients who were heterozygous for the DNA change. The variant enzyme, obtained by substitution of Ala for Ser445, showed an enhanced basal activity that was resistant to GTP inhibition but markedly sensitive to modification by estrogens. Thus, a gain-of-function rare polymorphism in hGDH2 hastens the onset of PD in hemizygous subjects, probably by damaging nigral cells through enhanced glutamate oxidative dehydrogenation. The lack of effect in female heterozygous PD patients could be related to a modification of the overactive variant enzyme by estrogens.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
de Rijk MC, Launer LJ, Berger K et al: Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54: S21–S23.
Hoehn MM, Yahr MD : Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427–424.
Elbaz A, Grigoletto F, Baldereschi M et al: Familial aggregation of Parkinson's disease: a population-based case-control study in Europe. EUROPARKINSON Study Group. Neurology 1999; 52: 1876–1882.
Wood NW : Genetic risk factors in Parkinson's disease. Ann Neurol. 1998; 44: S58–S62.
Spanaki C, Plaitakis A : Bilineal transmission of Parkinson disease on Crete suggests a complex inheritance. Neurology 2004; 62: 815–817.
Atlante A, Calissano P, Bobba A et al: Glutamate neurotoxicity, oxidative stress and mitochondria. FEBS Lett 2001; 497: 1–5.
Lin MT, Beal MF : Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006; 443: 787–795.
Plaitakis A, Berl S, Yahr MD : Abnormal glutamate metabolism in an adult-onset degenerative neurological disorder. Science 1982; 216: 193–196.
Iwasaki Y, Ikeda K, Shiojima T, Kinoshita M : Increased plasma concentrations of aspartate, glutamate and glycine in Parkinson disease. Neurosci Lett 1992; 145: 175–177.
Plaitakis A, Berl S, Yahr MD : Neurological disorders associated with deficiency of glutamate dehydrogenase. Ann Neurol 1984; 15: 144–153.
Plaitakis A, Shashidharan P : Glutamate transport and metabolism in dopaminergic neurons of substantia nigra: implications for the pathogenesis of Parkinson's disease. J Neurol 2000; 247: II/25–II/35.
Shashidharan P, Michaelidis TM, Robakis NK et al: Novel human glutamate dehydrogenase expressed in neural and testicular tissues and encoded by an X-linked intronless gene. J Biol Chem 1994; 269: 16971–16976.
Plaitakis A, Metaxari M, Shashidharan P : Nerve tissue-specific (GLUD2) and housekeeping (GLUD1) human glutamate dehydrogenases are regulated by distinct allosteric mechanisms: implications for biologic function. J Neurochem 2000; 75: 1862–1869.
Xiromerisiou G, Hadjigeorgiou GM, Gourbali V et al: Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson's disease: identification of two novel LRRK2 variants. Eur J Neurol 2007; 14: 7–11.
Papapetropoulos S, Ellul J, Paschalis C et al: Clinical characteristics of the alpha-synuclein mutation (G209A)-associated Parkinson's disease in comparison with other forms of familial Parkinson's disease in Greece. Eur J Neurol 2003; 10: 281–286.
Kang GA, Bronstein JM, Masterman DL et al: Clinical characteristics in early Parkinson's disease in a Central California Population-Based Study. Mov Disord 2005; 20: 1133–1142.
Gelb DJ, Oliver E, Gilman S : Diagnostic criteria for Parkinson's disease. Arch Neurol 1999; 56: 33–39.
Folstein MF, Folstein SE, McHugh PR : Mini-Mental State: a practical method for grading the state of patients for the clinician. J Psychiatr Res 1975; 12: 189–198.
Kanavouras K, Mastorodemos V, Borompokas N, Spanaki C, Plaitakis A : Properties and molecular evolution of GLUD2 (neural and testicular tissue-specific) glutamate dehydrogenase. J Neurosc Res 2007; 85: 1101–1109.
Cornish-Bowden A : Fundamentals of enzyme kinetics. London: Butterworth, 1979, pp 147–176.
Kuopio AM, Marttila RJ, Helenius H, Rinne UK : Changing epidemiology of Parkinson's disease in Southwestern Finland. Neurology 1999; 52: 302–308.
Van Den Eeden SK, Tanner CM, Bernstein AL et al: Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003; 157: 1015–1022.
Hudson RC, Daniel RM : L-glutamate dehydrogenases: distribution, properties and mechanism. Comp Biochem Physiol B 1993; 106: 767–792.
Stanley CA, Lieu YK, Hsu BY et al: Hyperinsulinism and hyperammonemia in infants with regulatory mutations of the glutamate dehydrogenase gene. N Engl J Med 1998; 338: 1352–1357.
Warren JC, Carr DO, Grisolia S : Effect of cofactors, estrogens and magnesium ions on the activity and stability of human glutamate dehydrogenase. Biochem J 1964; 93: 409–419.
Burki F, Kaessmann H : Birth and adaptive evolution of a hominoid gene that supports high neurotransmitter flux. Nat Genet 2004; 36: 1061–1063.
Zaganas I, Plaitakis A : Single aminoacid substitution (G456A) in the vicinity of the GTP binding domain of human housekeeping glutamate dehydrogenase markedly attenuates GTP inhibition and abolishes the cooperative behaviour of the enzyme. J Biol Chem 2002; 277: 26422–26428.
Plaitakis A, Spanaki C, Mastorodemos V, Zaganas I : Study of structure-function relationships in human glutamate dehydrogenases reveals novel molecular mechanisms for the regulation of the nerve tissue-specific (GLUD2) isoenzyme. Neurochem Int 2003; 43: 401–410.
Zaganas I, Spanaki C, Karpusas M, Plaitakis A : Substitution of Ser for Arg443 in the regulatory domain of human housekeeping (GLUD1) glutamate dehydrogenase virtually abolishes basal activity and markedly alters the activation of the enzyme by ADP and L-leucine. J Biol Chem 2002; 277: 46552–46558.
Rost B, Yachdav G, Liu J : The predict protein server. Nucleic Ac Res 2004; 32 (web server issue): W321–W326.
Smith TJ, Schmidt T, Fang J et al: The Structure of apo human glutamate dehydrogenase details subunit communication and allostery. J Mol Biol 2002; 318: 765–777.
Branden C, Tooze J : Motifs of Protein Structure; in Garland Publishing 2nd edition: Introduction to protein structure. New York, 1999, pp 13–34.
Stanley CA : Hyperinsulinism/hyperammonemias syndrome: insights into the regulatory role of glutamate dehydrogenase in ammonia metabolism. Mol Gen Metab 2004; 81: S45–S51.
Daikhin Y, Yudkoff M : Compartmentation of brain glutamate metabolism in neurons and glia. J Nutr 2000; 130: 1026S–1031S.
McKenna MC : The glutamate-glutamine cycle is not stoichiometric: fates of glutamate in brain. J Neurosc Res 2007; 85: 3347–3358.
Panov A, Dikalov S, Shalbuyeva N et al: Rotenone model for Parkinson disease. Multiple brain mitochondrial dysfunction after short term systemic rotenone intoxication. J Biol Chem 2005; 280: 42026–42035.
Acknowledgements
This study was supported by the Association for Research and Treatment of Neurologic Disorders of Crete (EY-ZHN) and by the Second Operational Programme for Education and Initial Vocational Training (EPEAEK II) to HL and CS from the Ministry of Education of Greece. We are grateful to PD patients and their families for participating in this study. We also thank Mrs M Rogdaki for her help in genetic studies.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on European Journal of Human Genetics website (http://www.nature.com/ejhg)
Supplementary information
Rights and permissions
About this article
Cite this article
Plaitakis, A., Latsoudis, H., Kanavouras, K. et al. Gain-of-function variant in GLUD2 glutamate dehydrogenase modifies Parkinson's disease onset. Eur J Hum Genet 18, 336–341 (2010). https://doi.org/10.1038/ejhg.2009.179
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/ejhg.2009.179
